A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
| Autor: | Genju Koh, Hiromune Takada, Takayuki Shiroyama, Kentaro Masuhiro, Chihiro Konishi, Norio Okamoto, Hiromi Kawasumi, Satomu Morita, Ayako Tanaka, Tomonori Hirashima, So Takata, Hidekazu Suzuki, Naoko Morishita, Shingo Nasu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
Afatinib Follicular lymphoma Case Report Metachronous Double primary malignant tumors FL follicular lymphoma EGFR-TKIs epidermal growth factor receptor-tyrosine kinase inhibitors 03 medical and health sciences 0302 clinical medicine NSCLC non-small cell lung cancer medicine Epidermal growth factor receptor LAD lung adenocarcinoma Lung cancer lcsh:RC705-779 Lung biology Performance status business.industry ALK anaplastic lymphoma kinase lcsh:Diseases of the respiratory system medicine.disease Synchronous CT computed tomography R-CHOP cyclophosphamide doxorubicin vincristine predonisone with rituximab medicine.anatomical_structure 030228 respiratory system 030220 oncology & carcinogenesis Cancer research biology.protein Adenocarcinoma business Tyrosine kinase medicine.drug |
| Zdroj: | Respiratory Medicine Case Reports, Vol 28, Iss, Pp-(2019) Respiratory Medicine Case Reports |
| ISSN: | 2213-0071 |
| Popis: | The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for follicular lymphoma was introduced in addition to continuing treatment with afatinib for lung cancer. Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. Our case study suggests that it is safe to introduce standard immunochemotherapy for patients who develop malignant lymphoma while continuing treatment with tyrosine kinase inhibitors for lung adenocarcinoma expressing mutant EGFR. Keywords: Lung cancer, Follicular lymphoma, Afatinib, Synchronous, Metachronous, Double primary malignant tumors |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|